Continued research into novel therapies, including those targeting less-studied cytokines such as IL-6 and IL-15 and the JAK/STAT pathway, is therefore essential for improving patient outcomes and may contribute to the development of personalized therapeutic strategies in SLE in the future. Here, IL6 is linked to systemic lupus erythematosus.